Esperion Files to Sell Stock

The company is proposing to sell 4 million common shares.
Author:
Publish date:

Esperion Therapeutics

(ESPR) - Get Report

filed a registration statement with the

Securities and Exchange Commission

to sell 4 million shares of the company's common stock.

All of the shares will be offered by the company. The underwriters will have an option to purchase up to 600,000 additional shares to cover any overallotments.

Lehman Brothers will act as bookrunner. Citigroup, Needham and U.S. Bancorp Piper Jaffray will act as co-managers.

Esperion, which is based in Ann Arbor, Mich., develops pharmaceuticals for treating cardiovascular disease. In recent

Nasdaq

trading, shares of Esperion were down 8 cents to $20.